A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12weeks

作者：Sparshatt A; Williams R H McAllister; Baldwin D S; Haddad P M; Bazire S; Weston E; Taylor P; Taylor D^*

来源：Acta Psychiatrica Scandinavica, 2013, 128(3): 203-211.

DOI：10.1111/acps.12044

• agomelatine
• depression
• effectiveness
• adverse effects

Objective: To determine the effectiveness of agomelatine in routine clinical practice and explore factors associated with response and continuation. %26lt;br%26gt;Method: Consecutive patients prescribed agomelatine in participating psychiatric services were included. Patient demographic and outcome data were collected at treatment initiation and then at weeks 4, 8 and 12. Outcomes were analysed with respect to clinical and demographic factors. %26lt;br%26gt;Results: A total of 110 patients from nine NHS trusts were followed through 12 weeks of treatment. Agomelatine was largely used in difficult-to-treat or refractory patients: 83 (75%) had failed to respond to, or relapsed on, prior antidepressants. There were high rates of physical (54.5%) and psychiatric (50.0%) comorbidity. At 12 weeks of treatment, 68 (62%) continued agomelatine treatment. Overall, 69 subjects (62.7%) improved by at least one point of the Clinical Global Impression (severity) scale. Of 42 who discontinued, 23 (56%) discontinued because of lack of efficacy and 10 (24%) due to an adverse event. Of all variables examined, only a history of more than five episodes of depression significantly predicted discontinuation of treatment (OR continuation -0.36, 95% CI 0.14, 0.95). %26lt;br%26gt;Conclusion: Agomelatine was effective and generally well tolerated in a cohort of difficult-to-treat patients in clinical practice.

• 出版日期2013-9